1-5 of 5
David A. Rizzieri, M.D.
Close
Sort by
Journal Articles

Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.

Sam O. Wanko, MD, Jon P. Gockerman, M.D, Joseph O. Moore, M.D, Carlos de Castro, M.D, Louis Diehl, M.D, Robert Pronitz, M.D, Cristina Gasparetto, M.D, John Chute, M.D, Mitchell Horwitz, M.D, Ashley Morris, Pharm.D, Francis Ali-Osman, PhD, Arati Rao, M.D, Donna Niedzweicki, PhD, Gwynn D. Long, M.D, Nelson J. Chao, M.D, David A. Rizzieri, M.D
Journal: Blood
Blood (2005) 106 (11): 5501.
https://doi.org/10.1182/blood.V106.11.5501.5501
Published: 2005
Journal Articles

The Use of DT388-IL3 Fusion Protein in Patients with Refractory Acute Myeloid Leukemia(AML).

Debashish Misra, M.D., Arthur Frankel, M.D., Philip Hall, Pharm.D., Tie Fu Liu, M.D., Jennifer Black, R.N., Joseph O. Moore, M.D., Carlos de Castro, M.D., Jon P. Gockerman, M.D., Cristina Gasparetto, M.D., Mitchell Horwitz, M.D., Patricia H. Davis, R.N., Nelson J. Chao, M.D., David A. Rizzieri, M.D.
Journal: Blood
Blood (2004) 104 (11): 4513.
https://doi.org/10.1182/blood.V104.11.4513.4513
Published: 2004
Journal Articles

Dose Dense, High Intensity Therapy in Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia Using Gemtuzumab Ozogamicin (Mylotarg™) and High Dose Cytarabine (HiDAC).

Arati V. Rao, M.D., David A. Rizzieri, M.D., Joseph O. Moore, M.D., Carlos DeCastro, M.D., Amy P. Abernethy, M.D., McLean Jordan, Patty Davis, Emily Edmonds, Jon P. Gockerman, M.D.
Journal: Blood
Blood (2004) 104 (11): 4516.
https://doi.org/10.1182/blood.V104.11.4516.4516
Published: 2004
Journal Articles

Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.

Sam O. Wanko, M.D, Jon P. Gocherman, M.D, Joseph O. Moore, M.D, Carlos Decastro, M.D, Robert Prosnitz, M.D, Cristina Gasparetto, M.D, John Chute, M.D, Mitchell Horowitz, M.D, Morris Ashley, Pharm.D, Edonds Emily, RN, Davis Patty, RN, Chao J. Nelson, M.D, David A. Rizzieri, M.D
Journal: Blood
Blood (2004) 104 (11): 1163.
https://doi.org/10.1182/blood.V104.11.1163.1163
Published: 2004
Journal Articles

Phase II Study of Thalidomide in Escalating Doses for Follicular (F-NHL) and Small Lymphocytic Lymphoma (Sll): CALGB Study 50002.

David L. Grinblatt, M.D., Jeffrey Johnson, Donna Niedzwicki, Ph.D., David A. Rizzieri, M.D., Nancy Bartlett, M.D., Bruce D. Cheson, M.D.
Journal: Blood
Blood (2004) 104 (11): 3284.
https://doi.org/10.1182/blood.V104.11.3284.3284
Published: 2004